Drug reference
Telavancin is a glycopeptide antibacterial; it has bactericidal activity against aerobic and anaerobic Gram-positive bacteria including multi-resistant staphylococci. However, there are reports of Staphylococcus aureus with reduced susceptibility to glycopeptides. There are increasing reports of glycopeptide-resistant enterococci.
PDF page 584
Hospital-acquired pneumonia, known or suspected to be caused by meticillin-resistant Staphylococcus aureus when other antibacterials cannot be used ▶BY INTRAVENOUS INFUSION ▶Adult: 10 mg/kg once daily for 7–21 days
PDF page 584
Conditions that predispose to renal impairment . predisposition to QT interval prolongation (including electrolyte disturbances, congenital long QT syndrome, uncompensated heart failure, severe left ventricular hypertrophy)
PDF page 584
Use with caution in patients with vancomycin or teicoplanin sensitivity.
PDF page 584
→Appendix 1: telavancin
PDF page 584
▶Common or very common Asthenia. constipation. diarrhoea. dizziness. headaches. increased risk of infection. insomnia. nausea. renal impairment. skin reactions. taste altered. urine abnormalities. vomiting ▶Uncommon Altered smell sensation. anaemia. angina pectoris. anxiety. appetite decreased. arrhythmias. arthralgia. Clostridium colitis. confusion. congestive heart failure. depression. drowsiness. dry mouth. dyspnoea. electrolyte imbalance. eye irritation. flatulence . flushing. gastrointestinal discomfort. haematuria. hepatitis. hiccups. hyperglycaemia. hyperhidrosis. hypertension. hypoglycaemia. hypotension. laryngeal pain. leucopenia. muscle complaints. nasal congestion. oedema. oral hypoaesthesia. pain. palpitations. paraesthesia. QT interval prolongation. red man syndrome. thrombocytopenia. thrombocytosis. tinnitus. tremor. urinary disorders. vision blurred ▶Rare or very rare Deafness
PDF page 584
Effective contraception required during treatment.
PDF page 584
Avoid (teratogenic in animal studies).
PDF page 584
Manufacturer advises avoid unless potential benefit outweighs risk—no information available.
PDF page 584
Manufacturer advises caution in severe impairment (no information available).
PDF page 584
Avoid in acute renal failure—risk of mortality increased. In chronic renal failure, avoid if eGFR less than 30 mL/minute/1.73 m2. Dose adjustments In chronic renal failure, use 7.5 mg/kg once daily if eGFR 30–50 mL/minute/1.73 m2.
PDF page 584
Monitor renal function daily for at least the first 3–5 days, then every 2–3 days thereafter.
PDF page 584
For intravenous infusion (Vibativ ®). Avoid rapid infusion (can cause ’red man’ syndrome). Give intermittently in Glucose 5% or Sodium chloride 0.9%; reconstitute each 750 mg with 45 mL glucose 5%, sodium chloride 0.9%, or water for injections to produce a 15 mg/mL solution; for doses of 150–800 mg, dilute requisite dose in 100 to 250 mL infusion fluid; for doses outside this range, dilute to a final concentration of 0.6–8 mg/mL; give over at least 60 minutes.
PDF page 584
There can be variation in the licensing of different medicines containing the same drug. Powder for solution for infusion ▶Vibativ (Clinigen Healthcare Ltd) Telavancin (as Telavancin hydrochloride) 750 mg Vibativ 750mg powder for solution for infusion vials | 1 vial P £645.00 (Hospital only)
PDF page 584
10 mg/kg once daily for 7–21 days
First-line fragment. Read the complete Indications and Dose section above.
PDF page 584
